Viscient Biosciences

Viscient Biosciences is a private, preclinical-stage biotech founded in 2014 that is pioneering a human-centric drug discovery platform. The company utilizes proprietary 3D human tissue models, validated to recapitulate complex diseases like fatty liver disease, combined with genomics and transcriptomics to identify novel disease-driver genes as therapeutic targets. Viscient has advanced one internally discovered drug to the preclinical stage and is in-licensing a second asset for Phase 2 studies, positioning itself to address the multi-billion dollar NASH market. The company is led by Keith Murphy, a seasoned executive and co-founder of the 3D bioprinting firm Organovo.

Integrated platform combining proprietary 3D human tissue models (validated to recapitulate complex diseases like NASH) with multi-omics analysis (transcriptomics, genomics, metabolomics) to identify novel disease-driver genes for therapeutic targeting.

Viscient competes in the crowded NASH drug development arena against numerous biopharma companies. Its differentiation lies in its discovery platform. It also competes in the broader organoid/tissue model space, where it must demonstrate superior disease modeling and drug discovery output compared to other academic and commercial efforts.